Close
Close
Treatment News

Receptos to Present at UBS Global Healthcare Conference

1.7 from 3 votes
Friday, May 15, 2015

Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced that management will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Times Square Hotel in New York City. The presentation is scheduled for Wednesday, May 20th at 12:00pm Eastern time.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, ozanimod (formerly RPC1063), is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune indications including relapsing multiple sclerosis and inflammatory bowel disease. Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for eosinophilic esophagitis (EoE), an allergic/immune-mediated orphan disease.

Contact:

Graham K. Cooper

Chief Financial Officer, Receptos

(858) 652-5708

gcooper@receptos.com

Source: Receptos, Inc.
1.7 from 3 votes
Free Newsletter
Videos
by Abidemi Uruejoma
60 views
by Abidemi Uruejoma
78 views
by Abidemi Uruejoma
83 views